$NMAD News

NOMAD Power Solutions Announces Third-Gen Voyager Mobile Energy Storage Series, Boosts Fleet-Wide Storage Capacity By 50%

LIXTE Joins Russell Microcap Index

LIXTE Biotechnology Set To Join Russell Microcap, Effective June 26

LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026

LIXTE Issues Update On NOMAD Acquisition; Loans $6.5M Pre‑Closing To Fund Order Backlog And Working Capital Needs; Combined Firm To Be Renamed NOMAD Power Solutions

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

LIXTE Biotechnology Announces ~$16.57M Registered Direct Offering, Selling ~2.625M Shares And Pre-Funded Warrants At A Combined Price Of $6.31

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

LIXTE Biotechnology To Seek Strategic Acquisition Partner For Its Clinical Stage Pharmaceutical And Med-Tech Business

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

Lixte Biotech Hldgs Q1 EPS $(0.18) Up From $(0.29) YoY

LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment

LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships

LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year

LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year